Vivos Therapeutics, Inc. (VVOS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Vivos Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Vivos Therapeutics, Inc. (VVOS) has returned -41.87% so far this year and -58.60% over the past 12 months.

Based on dividend-adjusted daily data since Dec 11, 2020, VVOS's average daily return is +0.39%, while the average monthly return is +4.04%. At this rate, your investment would double in approximately 1.5 years.

Historically, 34% of months were positive and 66% were negative. The best month was Nov 2023 with a return of +663.2%, while the worst month was Dec 2023 at -49.2%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 7 months.

On a daily basis, VVOS closed higher 42% of trading days. The best single day was Nov 29, 2023 with a return of +833.9%, while the worst single day was Nov 30, 2023 at -40.2%.

Vivos Therapeutics, Inc. has an annualized alpha of 139.16%, beta of 0.91, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since December 14, 2020.

• This stock participated in 245.93% of S&P 500 Index downside but only -41.15% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

VVOS ranks 15 for risk / return — in the bottom 15% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Vivos Therapeutics, Inc. (VVOS) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Vivos Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Vivos Therapeutics, Inc. was 99.55%, occurring on Mar 30, 2026. The portfolio has not yet recovered.

The current Vivos Therapeutics, Inc. drawdown is 99.51%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Vivos Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Vivos Therapeutics, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.